SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
128.80    4.60 (3.70%)
Bid:
128.20
Ask:
129.60
Spread: 1.40 (1.092%)
Market Cap: £536.34m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Pre-Close Trading Statement

25 Jul 2018 07:00

RNS Number : 6057V
James Halstead PLC
25 July 2018
 

25 July 2018

 

 

Pre-Close Trading Statement

 

 

James Halstead plc, the commercial flooring manufacturer and distributor, is providing the following trading update ahead of its final results for the year ended 30 June 2018.

 

We are pleased to report that sales for the year were ahead of the comparative year. This represents a creditable performance in still difficult trading conditions. It is particularly pleasing to report that our UK turnover is 3% ahead of the prior year in a market that seems to be quite robust despite the well reported spending cuts and high street retailer issues.

 

In the Chairman's interim statement, announced on 29 March 2018, it was noted that adverse price pressure on raw materials was holding back the benefits of export currency gains. This continued in the second half year but was ameliorated by increased sales. The Chairman, in that statement, noted that a German competitor had entered administration and at that time we decided to undertake our largest ever re-vamp of our homogenous flooring ranges with the launch of "Palettone."

 

Palettone is a premium homogenous sheet vinyl collection, launched in May 2018. It is the largest new product development by any manufacturer in this core product area in many years. It offers a collection of 50 colours optimised for our global market and is presented in a unique, innovative sample package with full customer support from specification to installation. The feedback we have received on the collection since launch has been exceptional.

 

The costs of development trials, sampling, marketing material and related costs have been around £2 million and the product has just been launched into the global market place. The timescale that our production and marketing staff worked to was ambitious and we are delighted with the successful launch.

 

In line with best practice, we shall expense these costs rather than amortise or construct an adjustment to "underlying" earnings.

 

Consequently we are pleased to anticipate, once again, reporting record turnover and expect profits for the year to 30 June 2018 will be in line with last year.

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

 

 

Enquiries:

 

 

Mark Halstead, Chief Executive

 

Gordon Oliver, Finance Director

Telephone: 0161 767 2500

 

 

Nick Lyon - Hudson Sandler

Telephone: 020 7796 4133

 

 

Ben Thorne

Dominic Morley - Panmure Gordon

(Nominated advisor and broker)

 

Telephone: 020 7886 2500

 

Chris Hardie - Arden Partners

Telephone: 020 7614 5900

(Broker)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBZLFLVDFEBBX
Date   Source Headline
1st Dec 20177:00 amRNSAGM Statement
20th Oct 20173:00 pmRNSAnnual Report & Accounts
2nd Oct 20177:00 amRNSBoard Changes
2nd Oct 20177:00 amRNSPRELIMINARY ANNOUNCEMENT OF AUDITED RESULTS
14th Sep 201712:42 pmRNSNotice of Preliminary Results
14th Sep 20177:00 amRNSNotice of Preliminary Results
1st Aug 201710:43 amRNSTotal Voting Rights
1st Aug 20177:00 amRNSPre-Close Trading Statement
31st Jul 20175:53 pmRNSDirector/PDMR Shareholding
3rd Jul 20175:40 pmRNSTotal Voting Rights
3rd Jul 20175:37 pmRNSBlock listing Interim Review
23rd Jun 20174:12 pmRNSDirector/PDMR Shareholding
12th Jun 201712:54 pmRNSDirector/PDMR Shareholding
9th Jun 20175:37 pmRNSTotal Voting Rights
12th May 20175:29 pmRNSDirector/PDMR Shareholding
12th May 20173:59 pmRNSDirector/PDMR Shareholding
5th Apr 20172:36 pmRNSDirector/PDMR Shareholding
29th Mar 20177:00 amRNSInterim Results
6th Mar 20177:00 amRNSNotice of Results
30th Jan 20177:00 amRNSPre Close Trading Statement
13th Dec 201611:13 amRNSResult of AGM
2nd Dec 20167:00 amRNSAGM Statement
1st Dec 20167:00 amRNSTotal Voting Rights
1st Nov 201612:24 pmRNSTotal Voting Rights
21st Oct 20167:00 amRNSAnnual Financial Report
3rd Oct 20167:00 amRNSPRELIMINARY ANNOUNCEMENT OF AUDITED RESULTS
21st Sep 20167:00 amRNSNotice of Preliminary Results
15th Aug 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
1st Aug 20167:00 amRNSPre-Close Trading Statement
1st Jul 20163:41 pmRNSBlock listing Interim Review
31st Mar 20167:00 amRNSInterim Results
8th Mar 20167:00 amRNSNotice of Interim Results
1st Feb 20164:51 pmRNSTotal Voting Rights
1st Feb 20167:00 amRNSPre Close Trading Statement
3rd Dec 20155:20 pmRNSDirector/PDMR Shareholding
1st Dec 20152:45 pmRNSTotal Voting Rights
27th Nov 201512:00 pmRNSChairman's Statement to the Annual General Meeting
2nd Nov 201511:39 amRNSTotal Voting Rights
29th Oct 20154:44 pmRNSDirector/PDMR Shareholding
23rd Oct 20159:45 amRNSAnnual Financial Report & Notice of AGM
29th Sep 20157:00 amRNSFinal Results
18th Sep 20157:00 amRNSNotice of Preliminary Results
31st Jul 20157:00 amRNSTotal Voting Rights
29th Jul 20157:00 amRNSPre-Close Trading Statement
28th Jul 20156:00 pmRNSBlocklisting Interim Review
24th Jul 20155:00 pmRNSDirector/PDMR Shareholding
1st Jul 20157:00 amRNSChange of Adviser
3rd Jun 20157:00 amRNSTotal Voting Rights
31st Mar 20157:00 amRNSInterim Results
20th Mar 20154:31 pmRNSNotice of Results - Replacement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.